Are these 3 top stocks still mighty income machines?

The search for a higher yield on your savings should start with these three stocks, says Harvey Jones.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Everybody needs a few income machines to keep their portfolio ticking over. Here are three you can’t afford to ignore.

GlaxoSmithKline

Pharmaceuticals giant GlaxoSmithKline (LSE: GSK) has been called an income machine for as long as I can remember and despite the odd glitch it keeps pumping out the dividends. The share price has also impressed lately, growing 20% in the past three months, which has knocked the yield to 4.81%. Given that this is almost 20 times the current base rate, it seems churlish to complain.

Glaxo’s 4% increase in turnover over the second quarter (at constant exchange rates) and 16% leap in core earnings per share (EPS) satisfied markets. Key to the company’s long-term prospects are sales from new products and here the news is good, as they now account for 23% of total pharmaceutical sales, offsetting continuing declines in Seretide/Advair. The dividend has been frozen at 80p for several years but is still a tonic in today’s low yield world.

Royal Mail

Royal Mail (LSE: RMG) is a relatively new income play but looks set to keep churning out the dividends for years to come. The existential question is whether its parcels business can expand fast enough to overcome the inevitable decline in the old-fashioned letter. Its latest trading update showed a 1% rise in group revenue, offsetting a 1% decline in UK revenues, exciting nobody either way. 

Similarly, a 2% rise in parcels volumes and revenues had to be judged against the 2% drop in UK addressed letter volumes and 3% drop in letter revenues. Double-digit growth in Europe suggests Royal Mail could deliver some excitement but the general message is ‘slow and steady goes’, amid challenging economic seas. This impression is confirmed by forecast EPS growth of 0% until March 2017, followed by 3% in 2018. But a forecast dividend of 4.7% is attractive and healthy cover make this a good buy for income seekers, especially at 12.48 times earnings.

Vodafone Group

The phrase income machine could almost have been coined for mobile phone giant Vodafone (LSE: VOD). It continues to do what it has done for as long as I can recall, that to yield around 5% a year. Right now you get 4.87%, pretty much in range. The share price is up 44% over the past five years, which is solid for a company that few people buy for its growth prospects.

First quarter revenues grew 2.2%, although they fell 4.5% in reported terms on negative foreign exchange movements, as Vodafone reports in euros. It has made big strides in selling larger data bundles and fixed broadband services across its key markets, with a whopping 63% growth in data traffic across the quarter, plus an extra 5.7m on its 4G customer base, which has doubled year-on-year to 52.5m. Data revenues, however, aren’t rising at anything like that pace and despite rapid growth in Turkey and India, Europe continues to hold the business back. That said, forecast EPS growth of 38% in the year to March 2017 and 13% the year after is promising. By then the stock is expected to yield 5.1%, which is pretty much what you would expect.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Harvey Jones has no position in any shares mentioned. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Market Movers

Here’s why the Unilever share price is soaring after Q1 earnings

Stephen Wright isn’t surprised to see the Unilever share price rising as the company’s Q1 results show it’s executing on…

Read more »

Investing Articles

Barclays’ share price jumps 5% on Q1 news. Will it soon be too late to buy?

The Barclays share price has been having a great time this year, as a solid Q1 gives it another boost.…

Read more »

Young black colleagues high-fiving each other at work
Investing Articles

The AstraZeneca share price lifts 5% on a top-and-bottom earnings beat

The AstraZeneca share price reached £120 today and helped push the FTSE 100 higher. Would I still buy this flying…

Read more »

Young black woman using a mobile phone in a transport facility
Market Movers

Meta stock slumps 13% after poor results. Here’s what I’ll do

Jon Smith flags up the reasons behind the fall in the Meta stock price overnight, along with his take on…

Read more »

Young Caucasian girl showing and pointing up with fingers number three against yellow background
Investing Articles

3 FTSE stocks I wouldn’t ‘Sell in May’

If the strategy had any merit in the past, I see no compelling evidence it's a smart idea today. Here…

Read more »

Investor looking at stock graph on a tablet with their finger hovering over the Buy button
Investing Articles

Down 21% and yielding 10%, is this income stock a top contrarian buy now?

Despite its falling share price, this Fool reckons he's found an income stock that could be worth taking a closer…

Read more »

Investing Articles

The Meta share price falls 10% on weak Q2 guidance — should investors consider buying?

The Meta Platforms' share price is down 10% after the company reported Q1 earnings per share growth of 117%. Does…

Read more »

Investing Articles

This FTSE 250 defence stock looks like a hidden growth gem to me

With countries hiking defence spending as the world grows more insecure, this FTSE 250 firm has seen surging orders and…

Read more »